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Aims: Painful diabetic peripheral neuropathy (PDPN) is a common complication of diabetes
mellitus. A systematic literature review was conducted to provide an overview of published
literature in the last 10-years on the epidemiology, humanistic burden and economic burden
of PDPN in Europe.
Methods: A search was performed according to pre-defined strategy and review criteria in
Embase, Pubmed, and conference proceedings databases from 2003 till December 2012. In
total, 30 publications written in English covering the relevant patient population and topics
of interest.
Results: European prevalence ranges from 6% to 34% in diabetes mellitus patients. PDPN has
a significant humanistic and economic impact. Patients are limited in their general func-
tioning and their ability to sleep and often experience anxiety and depression. Not surpris-
ingly, PDPN is associated with reduced Health-Related-Quality-of-Life (HRQoL). PDPN
patients incur high health care costs due to hospitalizations and outpatient visits. In
addition, the painful symptoms cause impaired work productivity. Studies suggest both
humanistic and economic burden increase with higher pain severity.
Conclusions: The burden from PDPN appears to be higher with increasing pain severity. More
severe pain leads to a higher impairment in daily functioning, sleep and HRQoL. Higher pain
intensity also leads to increasing healthcare costs and work productivity losses.
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Diabetic polyneuropathy (DPN) is one of the most common
complications of diabetes and the most common form of
neuropathy in the developed world [1]. Clinical manifestations
of DPN include painful diabetic neuropathy (PDPN), trouble-
some autonomic features such as orthostatic hypotension [2],
cardiac autonomic neuropathy (a clinical condition which can
result in sudden death) [3], other conditions caused by non-
cardiac autonomic neuropathy (such as gastro-paresis and
erectile dysfunction) [3], and insensitivity to trauma (which
can result in ulceration, infections, and lower extremity
amputations) [2].
PDPN develops as a result of damage to or dysfunction of
the system that signals pain [4]. Patients suffering with PDPN
describe symptoms as burning, aching, shooting, and stab-
bing; usually with nocturnal exacerbations [1,5]. PDPN is often
present in arms, hands, legs, and feet. It can affect the ability
of patients to perform daily activities, their sleep, their work,
how they feel, and therefore reduce the enjoyment of life for
these patients [6]. Health related quality of Life (HRQoL), sleep
and mood are frequently impaired in patients with PDPN [6,7].
Generally, pain reduction (as a result of treatment) is related to
improvement in QoL [8,9].
The only intervention that has been shown to reduce the
risk of development of neuropathy in diabetes patients is
intensive glucose control [1,10]. Apart from suboptimal
glycaemic control, patients with longer diabetes duration, of
older age, hypertensive, with cardiovascular disease or who
smoke are more likely to develop diabetic neuropathy [1].
In Europe, duloxetine is recommended as the first-line
treatment option for PDPN, by the European Federation of
Neurological Societies (EFNS) [9] and the National Institute for
Health and Clinical Excellence (NICE) [4]. Pregabalin, gaba-
pentin, amitriptyline, other tricyclic antidepressants (TCAs),
tramadol, topical lidocaine, strong opioids and a combination
of these drugs are advised as second-line and third-line
treatments; the choice of drug(s) is made on an individual
patient basis. Large studies are required to better define
patient responder profiles for specific drug treatments [9].
Although a wide range of treatment options are available, an
unmet need among PDPN patients still exists since neuropathic
pain is often difficult to treat due to the resistance to many
medications or due to their associated adverse effects. Many
people require treatment with more than one drug, but the
correct choice of drugs and the optimal sequence for their useis so far unknown [4]. The use of multiple drugs (polypharmacy)
may also increase the risk of additional adverse events and
incorrect use of medication [11].
Due to their pain, PDPN patients are expected to incur
higher health care costs compared to the general population
and diabetes patients without PDPN as they take pain reducing
medication and are likely to visit health care professionals
more frequently. In addition, the absence from work or
reduced functionality at work can result in additional costs for
society.
The objective of this literature review was to collect and
discuss European data regarding the epidemiology, humanis-
tic and economic burden associated with PDPN in order to
provide a complete overview from a European perspective of
the evidence published in the last 10 years. The research
questions to be answered by the review are ‘What is the
prevalence and incidence of PDPN?’, ‘What are the identified
risk factors and patient subgroups in PDPN?’, ‘How are PDPN
patients affected in their general functioning, sleep, anxiety,
depression and overall HRQoL?’ and ‘What is the resource use
associated with PDPN, including direct and indirect costs?’
2. Literature review process
2.1. Search strategy
A systematic literature search was performed to obtain
available European literature on epidemiology, and the
humanistic and economic burden associated with PDPN. In
addition, the search included publications on PDPN manage-
ment to provide background information regarding current
treatment patterns. Before commencing the search, a protocol
was developed following the PRISMA statement [12].
Embase and PubMed were searched for relevant publica-
tions from January 2003 to December 13th 2012. Websites of
European Health Technology Assessment (HTA) organizations
and conference proceedings from the International Associa-
tion for the Study of Pain (IASP) were searched from January
2010 to December 13th 2012. These last two sources were
searched for the last 3 years only, as it is expected that
abstracts of high quality are highly likely to be published in
peer reviewed journals during this period. Disease terms for
PDPN were combined with search terms for the topics of
interest, such as epidemiology, prevalence, incidence, hu-
manistic burden, quality of life, comorbidities, anxiety,
depression, healthcare cost, budget impact, resource use,
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care.
Publications were included in the review if they contained
all of the following criteria (1) concerned PDPN patients; (2)
contained data for epidemiology, humanistic burden or
economic burden; (3) had a European scope; (4) were written
in the English language; and (5) were full-texts or conference
abstracts of original studies.
For studies reporting costs in currencies other than Euros,
the amounts were converted to Euros using the conversion
rate of March 2013 [13]. Euro and the original currency (in
brackets) are reported in the text.
2.2. Search results
A total of 1694 citations were obtained via Embase and PubMed
and 185 via other databases. After removing duplicates, 1485
titles and abstracts were screened, and 238 full texts were
assessed for eligibility (Fig. 1). Main reasons for exclusion:
articles not addressing PDPN, not describing one of the
relevant topics, not an original study or with no European
scope. The search resulted in the inclusion of 33 publications
covering 30 different studies. Table 1 provides an overview of
included studies and key characteristics.
Thirteen articles reported on epidemiology [14–26], 10
on humanistic burden [27–36] and three on economic burden
[37–39]. Seven studies provided data for both humanistic
burden and epidemiology (n = 3) [40–42] or economic burden
(n = 4) [43–46]. Most epidemiology and humanistic burden
studies were performed in the UK (n = 5 [14,16,18,40,41] and
n = 7 [27,28,33,35,40,41,44], respectively). Economic burden
studies were performed in Spain (n = 3) [38,43,45], UK (n = 2)
[37,44] and Europe (n = 2) [39,46]. The majority of included
studies were cross-sectional by design (n = 15) [14–16,19,21,22,Records  idenﬁed  through 
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Fig. 1 – PRISM24,27,28,34,35,39,40,42,46]; the remainder were retrospective
database studies (n = 9) [17,18,20,23,25,26,37,38,41], cohort
studies (n = 6) [29–33,36] and economic evaluations (n = 3)
[43–45].
Included studies used a range of different methods to
determine whether patients met the PDPN criteria (see
Table 1). Seven studies based their criteria on completed
questionnaires [14,15,24–26,33,40], most frequently used
questionnaire was the Michigan Neuropathy Screening In-
strument (MNSI). Other studies included patients based on
medical record status [17,18,20,23,27,41], clinical examination
[16,19,21,22,40], physician diagnosis [15,42,46] or International
Classification of Diseases (ICD) codes [28,37,38]. Eleven studies
did not report the methods or criteria they applied [29–32,
34–36,39] or it was not relevant for the study design (i.e.,
economic model) [43–45].
3. Epidemiology
PDPN is a common comorbidity among diabetes patients; the
reported prevalence of PDPN in Europe ranged from 0.7% to
34% in overall, type1 or type 2 diabetes mellitus patients (see
Table 2). Excluding outliers, the prevalence range was found to
be 5.8–34% [14–16,19–22,24,26,40]. The incidence rate of PDPN
was reported to be 0.72 per 1000 persons per year for the
Netherlands [17], and 0.64–0.69 per 1000 persons per year in
the UK [18,41].
Identified risk factors for PDPN were older age, female
gender, type 2 diabetes mellitus, and longer duration of
diabetes [14,16,19,21,22,24,25,40]. None of the included studies
investigated risk factors as the main study objective.
The literature review identified few studies focusing on
PDPN subgroups. One German cross-sectional study by Baronl records  idenﬁed 
her sources  (n=185)
)
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Table 1 – Overview of included studies.
First author,
publication year
Topic Country N Study design Sponsor Method to determine
PDPN
Abbott 2011 [14] Epidemiology UK 15,692 Observational–Cross-
sectional
Department of health Questionnaire (NDS)
Bouhassira 2011 [15] Epidemiology France 766 Observational–Cross-
sectional
No sponsor disclosed Physician diagnosis and
questionnaires (DN4, MNSI)
Daousi 2004 [16] Epidemiology UK 694 Observational–Cross-
sectional
No sponsor disclosed Clinical examination
Dieleman 2008 [17] Epidemiology The
Netherlands
362,693 Observational–Database Pfizer Medical records
Hall 2008 [18] Epidemiology UK 2.9 million Observational–Database Pfizer Medical records
La Cesa 2011 [19] Epidemiology Italy 353 Observational–Cross-
sectional
No sponsor disclosed Clinical examination
Rubino 2007 [20] Epidemiology Europe 913 Observational–Database Eli Lilly and company Medical records
Truini 2011[21] Epidemiology Italy 353 Observational–Cross-
sectional
No sponsor disclosed Clinical examination
Van Acker 2009 [22] Epidemiology Belgium 1111 Observational–Cross-
sectional
Pfizer Clinical examination
Van Kollenburg 2012 [23] Epidemiology The
Netherlands
497 Observational–Database No sponsor disclosed Medical records
Wu 2007[24] Epidemiology France 14,352
(households)
Observational–Cross-
sectional
Eli Lilly and company
and Boehringer
Ingelheim
Questionnaire (MNSI)
Ziegler 2009a [25] Epidemiology Germany 393 Observational–Database Research institute Questionnaire (MNSI)
Ziegler 2009b [26] Epidemiology Germany 393 Observational–Database Research institute Questionnaire (MNSI)
Davies 2006 [40] Epidemiology
humanistic burden
UK 385 Observational–Cross-
sectional
Pfizer Questionnaire (DNSS) and
clinical examination
Hall 2006[41] Epidemiology
humanistic burden
UK >6.8 million Observational–Database Pfizer Medical records
Baron 2009 [42] Epidemiology
humanistic burden
Germany 1623 Observational–Cross-
sectional
Pfizer Physician diagnosis
Cash 2012 [27] Humanistic burden UK 300 Observational–Cross-
sectional
No sponsor disclosed Medical records
Currie 2006 [28] Humanistic burden UK 1298 Observational–Cross-
sectional
Eli Lilly and Company ICD codes
D’Amato 2012 [29] Humanistic burden Italy 33 Observational–Cohort No sponsor disclosed Not reported
Schneider 2011a [30] Humanistic burden Germany 2576 Observational–Cohort No sponsor disclosed Not reported
Schneider 2011b [31] Humanistic burden Germany 2576 Observational–Cohort No sponsor disclosed Not reported
Spallone 2012 [32] Humanistic burden Italy 105 Observational–Cohort No sponsor disclosed Not reported
Tahrani 2011 [33] Humanistic burden UK 204 Observational–Cohort Research institute Questionnaire (MSNI)
Taylor-Stokes 2012a [34] Humanistic burden Europe 634 Observational–Cross-
sectional
Pfizer Not reported
Thomas 2012 [35] Humanistic burden NA (UK) 113 Observational–Cross-
sectional
No sponsor disclosed Not reported
Vileikyte 2009 [36] Humanistic burden US and UK 495 Observational–Cohort Patient organization Not reported
De Salas-Cansado 2012 [43] Humanistic burden
economic burden
Spain 189 Economic evaluation Pfizer NA (model)
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neuropathy sensory symptoms [42]. Based on patient-reported
pain symptoms (i.e., burning, allodynia, thermal pressure,
pricking, pain attacks, and numbness), five different sensory/
neuropathy profiles were developed showing remarkable
differences in the expression of symptoms. For instance,
the prominent features of the first profile are moderate to
strong spontaneous burning pain in combination with slight to
moderate dynamic mechanical allodynia (DMA), while the
dominant symptoms of the second profile are severe and
clinically relevant pain attacks. The study did not investigate
how these different profiles influence quality of life or
treatment effects. Whether patients with various symptom
profiles are likely to respond differently to different pain
treatments, and how this information can be used to
develop optimal treatment pathways, requires further inves-
tigation.
Pain severity can also be used to divide PDPN patients into
subgroups; a commonly used classification is a division into
mild, moderate, and severe. This division is based on the
measurement of pain scores, using instruments such as the
Numeric Rating Scale (NRS), Brief Pain Inventory (BPI), Toronto
Clinical Scoring System (TCSS), or The Neuropathy Total
Symptom Score-6 (NTSS-6) scores [28,37,40,47,48]. For NRS [47]
and BPI [48] scores range from 0 to 10, where 0 is no pain and 10
is worst imaginable pain. For NTSS-6, PDPN symptom
severities can be classified as none (0), mild (>0 and 3.33),
moderate (>3.33 and 7.64) and severe (>7.64 and 10) [28].
Studies reported 15.7–36.4% of patients to have mild
symptoms; 13.8–57.1% to have moderate pain; and 10–35%
to have severe pain (as measured with the instruments
described above) [24,30,40,46]. None of the included studies
investigated how these subgroups could be helpful for
determining treatment patterns; however, the following
sections will outline that higher pain severity is associated
with a higher disease burden and higher economic burden.
4. Humanistic burden
The pain experienced by PDPN patients can considerably
affect their daily life by reducing the ability to walk and/or
perform general everyday activities. The pain and associated
impairment of daily living also affect the mood of patients
and how they value the quality of their life. Concomitant
medication use is high in these patients; a patient survey
shows 43% of PDPN patients received prescription medica-
tions for sleep disturbance, anxiety and/or depression [46].
The interference of pain with general activity, mood,
walking, work, relationships, sleep, and enjoyment of life is
measured with the BPI interference score; where 0 is no
interference and 10 is complete interference [46]. On this scale,
PDPN patients score 4.8 for overall pain interference; with
subscales for walking ability and general activity being most
affected [30,31,46]. The scores on the subscales for sleep, mood
and enjoyment of life are almost as equally highly impaired as
walking and general activity, only the subscale ‘relationships’
is less affected by PDPN [46]. The BPI score measured in PDPN
patients is comparable to osteoarthritis (OA); a baseline BPI
score of 5.1 was found in OA patients [49].
Table 2 – Reported PDPN prevalence and incidence.
Study Prevalence/incidence rate Diagnosis method
Van Kollenburg 2012 [23] Prevalence PDPN: 0.7% from the studied diabetic
patients in the nursing home had PDPN and 0.7%
had possible PDPN.
PDPN diagnosis based on medical record
Abbott 2011 [14] The overall prevalence of painful neuropathy
symptoms in this cohort was 34% of the diabetic
population.
PDPN diagnosis based on NSS score 5 and NDS
score 3
La Cesa/Truini 2011 [19,21] Prevalence PDPN: 18% of the diabetic patients had
neuropathic pain (50% of total diabetic study
population)
PDPN diagnosis based on DN4 questionnaire
Bouhassira 2011 [15] Prevalence PDPN: 20.8% in the diabetic study
population.
PDPN diagnosis method not reported
Ziegler 2009a [25] Prevalence PDPN: 13.3% of diabetic patients PDPN diagnosis based on MNSI questionnaire
Van Acker 2009 [22] Prevalence PDPN: 14% (over all); 17.9% in diabetes
type 1 patients; 5.8% diabetes type 2 patients.
Neuropen and DN4 were used to assess PDPN
Wu 2007 [24] Prevalence PDPN in diabetic patients: 8% PDPN diagnosis based on MNSI score >7
Rubino 2007 [20] Prevalence PDPN Approximately 50% of the DPN
patients experienced pain. (The proportion of
patients with diabetes diagnosed with DPN ranged
from 9.6% to 23.1%)
PDPN diagnosis method not reported
Davies 2006 [40] Prevalence PDPN: 26.4% of patients with type 2
diabetes
PDPN diagnosis based on the Toronto clinical
scoring system
Daousi 2004 [16] Prevalence PDPN: 16.2% in diabetes patients
compared with 4.9% in the age and sex-matched
control group.
PDPN diagnosis based on a Pain symptom score 3,
NSS score 5 and NDS score 3
Dieleman 2008 [17] Incidence PDPN: 0.72 per 1000 persons per year PDPN diagnosis based on medical record of patients
Hall 2006 [41] Incidence PDPN: 15.3 per 100,000 person years PDPN diagnosis based on medical record of patients
Hall 2008 [18] Incidence PDPN: 27.2 per 100,000 person years PDPN diagnosis based on medical record of patients
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 9 ( 2 0 1 5 ) 2 1 5 – 2 2 5220The impact of PDPN on daily living, measured with disease
specific instruments, also show that PDPN patients have
impaired functioning. Patients score 2.51 with the Neuro-QoL
activities of daily living scale; where 1 is no interference and
5 is high interference [36]. On the Sheehan disability scale,
PDPN patients show a mean value of 15, on a scale from 0
(unimpaired) to 30 (highly impaired) [30]. In comparison, a
recent study in epilepsy patients found a mean score of 13.9
on the Sheehan disability scale [50].
Due to nocturnal pain, PDPN is often associated with sleep
disturbance; it has been reported that 72–96% of patients are
moderately to severely affected in their sleep [35,42]. PDPN
patients showed significantly worse scores on The Medical
Outcomes Study-Sleep Scale (MOS-SS), particularly in the
items of ‘sleep adequacy’ and ‘awaken short of breath’ or ‘with
headache’, compared to both diabetes patients without
neuropathy and diabetes patients with any other form of
neuropathy [29,32]. Cash et al. 2012 reported sleep interruption
to be significantly correlated with PDPN severity in a linear
regression analysis ( p < 0.001) [27].
The continuous pain, interference with patients’ daily lives
and uncertainty about successful treatment are associated
with symptoms of anxiety and/or depression. Studies mea-
suring this with the Hospital Anxiety and Depression Scale
(HADS) or the Patient Health Questionnaire 9 (PHQ-9) found
that 24.5–72.1% of PDPN patients had symptoms of depression
and/or anxiety [27,30,36,42]. The study by Hall et al. 2006 found
that 21.6% of PDPN patients had a diagnosis of depression in
their medical record [41].
Higher pain severity is found to be significantly correlated
with higher interference of daily living and sleep [27,34]. SF-36
scores (in brackets) for physical functioning decrease withincreasing severity: no symptoms (74.93), mild symptoms
(48.07), moderate symptoms (45.04), and severe symptoms
(23.81) [28]. Recent published mean SF-36 physical functioning
scores were 60.8 for epilepsy patients and 62.3 for asthma
patients [51].
Furthermore, the negative impact of PDPN on the daily lives
of patients is reflected in poor HRQoL and low observed utility
values in PDPN patients. PDPN patients had significantly
worse QoL (measured by NeuroQoL) compared with diabetes
mellitus patients with no pain and those with non-neuro-
pathic pain [40].
Comparable to daily activities and sleep, a significant
relationship exists between pain severity and QoL. This
relationship has been shown by measurements with both
disease-specific (NeuroQol) [28,40] and different generic
HRQoL instruments (EQ-5D, SF-36) [28,46,48]. Mean EQ-5D
health state valuations were 0.81, 0.59–0.63, 0.43–0.52, and
0.20–0.25 for no, mild, moderate, and severe pain, respectively
(Fig. 2) [28,46].
5. Economic burden
Several studies have been identified showing that PDPN
patients induce high health care costs and have impaired
productivity.
A European study reported 76% of patients visited their
physician at least once in the past 4 weeks [46]. Telephone
consultations in the previous 4 weeks were reported by 25% of
patients, and slightly less than half of the patients (43%)
reported having been evaluated by a pain specialist [46]. In a
UK study, the number of GP contacts per 6 weeks ranged from
Fig. 2 – Burden of PDPN related to pain severity * Currie 2006 [37]. Direct costs included inpatient, outpatient, general
practitioner, nurse, other professional, and drug costs from an UK NHS perspective. ** To¨ lle et al. 2006 [46]. (Amounts were
converted to Euros using the conversion rate of March 2013 [13]). *** Taylor-Stokes 2012 [39]. Lost productivity (assessed by
the Work Productivity and Activity Impairment scale (WPAI)) costs were calculated using average annual wages for 2008 in
the EU.
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[37].
The resource use of PDPN patients results in mean annual
per patient UK health care costs of s2,963 (£2,511); 41% of these
costs accounted for inpatient care [37]. These annual costs are
comparable to those found in a Spanish national health
system (NHS) database study, presenting mean annual costs
of s2,476 per patient when pregabalin or gabapentin was
added to usual care [38]. Modeled healthcare costs from the
Spanish NHS perspective found similar costs per year of
s2,441 when patients were treated with usual care (which
could include antidepressants, opioids, anticonvulsants other
than pregabalin, and/or any analgesics according to the
physician’s medical practice) or pregabalin plus usual care;
with medical visits accounting for 34% of healthcare costs [43].
Drug costs accounted for 30–32% of healthcare costs in the
included studies [37,43]. Per patient drug costs can vary widely
depending on the choice of medication. Costs of generic anti-
depressants are low compared to the newer branded medica-
tions, though the evidence base for anti-depressants within
the PDPN population is less substantiated [4].
None of the studies reviewed compared resource use or
health care costs with other diseases, and therefore do notindicate whether PDPN patients use more resources compared
to, for example, non-PDPN diabetes patients. Studies found
higher resource use and direct costs when the pain severity
of the PDPN patients increased [37,46]. Annual healthcare
costs ranged from s1,902 to s3,795 (£1,612 - £3,217) per patient
for different levels of pain severity (Fig. 2). General linear
modeling indicated that the PDPN severity score NTSS-6
(classified as none/mild/moderate/severe) was a significant
predictor of both annual health resource costs and yearly
prescribed drug costs. On average, each 1-point increase in
NTSS-6 score predicted a 6% increase in primary and
secondary care costs and a 3% increase in log transformed
drug costs. The same study showed that gender, age, type of
diabetes, duration of diabetes and BMI were not significant
predictors for health care use and costs [37].
PDPN is significantly associated with disruptions in
employment status and work productivity losses. In a UK
cross-sectional study approximately 35% of the PDPN patients
reported some level of disruption due to pain; 59% of the
working patients reported being less productive at work at
least some of the time. Pain severity was also significantly
associated with interruption in employment. While only
14% of patients with mild pain reported pain-related work
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patients (38%) and more than tripled for severe pain patients
(48%) [46].
Disturbance in employment status resulted in European
productivity losses of s10,484 per patient per year [39].
Productivity losses were similar among the included European
countries and were primarily driven by presenteeism (im-
pairment while working) [39]. Also, annual lost productivity
cost increased with pain severity. Estimated annual produc-
tivity losses based on several European countries were s5,646,
s10,552, and s16,597 for mild, moderate, and severe PDPN,
respectively (Fig. 2).
The literature review did not identify any evidence
regarding total budget implications of PDPN for European
countries from either a health care or societal perspective.
6. Discussion
European prevalence of PDPN ranges from 5.8% to 34% in
patients with diabetes. The reported prevalence of PDPN in
Europe in all identified studies ranged from 0.7% to 34% in
diabetes mellitus patients. The value 0.7% is assumed to be an
outlier, since the study was conducted in nursing homes. The
majority of the included population was 75 years of age;
therefore, the study sample is not comparable to the general
diabetes population [23].
None of the studies investigated risk factors as the main
study objective. Large risk factor studies have been conducted,
but these results were published before 2003 and therefore not
included in our search results. An example of a large risk factor
study is the European diabetes research project (Eurodiab
study), where it was discovered that suboptimal glycaemic
control is a major determinant for developing diabetic
peripheral neuropaty [1]. Furthermore, there is a possibility
that not all relevant risk factors have been investigated yet;
Van Acker et al. (2009) suggested that body height might
influence the development of PDPN [22].
The studies identified in the literature review show that
PDPN is burdensome from both humanistic and economic
perspectives. PDPN patients are limited in their general daily
functioning and their ability to sleep. Furthermore, the pain
and limitations on daily activities and functioning are
associated with symptoms of anxiety and depression in many
patients. Not surprisingly, PDPN patients experience a low
overall HRQoL as a result of their symptoms. PDPN patients
induce high health care costs due to hospitalizations and
outpatient visits. In addition, the painful symptoms cause
impaired work productivity.
Intervention studies (e.g., clinical trials) were excluded in
this literature review. Therefore, in the studies included in this
literature review patients could be receiving (neuropathic)
pain medication. Unfortunately it is not always clearly
specified in the included studies. As a result, the reported
humanistic burden in the included studies could be on average
underestimating the real-life burden of PDPN patients which
would not receive (neuropathic) pain medication.
The burden from PDPN appears to be higher with
increasing pain severity. Increased pain intensity leads to a
higher impairment in daily functioning, sleep and HRQoL. Thisrelationship also applies to healthcare costs and productivity
losses related to PDPN; more severe pain leads to higher costs
from healthcare and societal perspectives.
Compared to diabetes patients with other complications
and comorbidities such as heart disease, COPD, and stroke,
PDPN patients have the lowest EQ-5D utility value (0.63, 0.65,
0.56 vs. 0.41) [46,52]. Compared to other chronic diseases such
as asthma, Parkinson’s disease, and depression the utilities
from PDPN patients are lowest (0.89, 0.67, and 0.47 vs. 0.41,
respectively) [46,53–55].
The low utility values for PDPN patients can be explained by
the large influence of pain on EQ-5D scores. This is reflected in
the EQ-5D UK value sets. When EQ-5D index values are
determined, pain/discomfort has larger influence on the
values than mobility, self-care, usual activities, and anxiety/
depression [56].
Due to PDPN being a chronic condition and the impact of
PDPN on patients daily life, patients place a high value on
obtaining relief from painful symptoms [46]. Patients with
higher pain severity have a relative lower QoL and this
relationship between pain severity and utilities appears to be
non-linear [48,57,58]. Therefore it is expected that reducing
pain in patients with more severe symptoms results in a larger
QoL gain. Hoffman et al. 2010 reported patients in the ‘‘severe-
to-moderate’’ pain group had a greater mean improvement in
the health status score than those in the ‘‘moderate-to-no/
mild’’ pain group after treatment. It is suggested that patients
whose pain is not reduced with treatment to a mild level of
severity can still experience clinically important changes in
health status [48].
Data regarding economic burden of PDPN, such as resource
use and real-life costs, was rather limited. Identified publica-
tions mainly concerned direct health care costs in the UK and
Spain [37,38] or resource use and productivity losses at a
European level [39,46]. None of the studies compared the results
for PDPN patients directly to non-PDPN patients or to the
general population. In addition, no publication was found
estimating the total economic burden of PDPN for a European
country. Future research for these evidence gaps would provide
valuable information about the economic burden of PDPN.
The key strength of this review is its broad scope including
European epidemiology, humanistic burden, and economic
studies. The search was not restricted to Embase and PubMed
databases, but also included websites of European HTA
organizations and conference proceedings from the IASP to
ensure relevant evidence not included in peer reviewed
journals was obtained.
The literature review has some limitations. All studies
included in the review contained data concerning PDPN
patients, however, there is variation between studies on how
PDPN was defined and assessed. For instance, epidemiology
studies evaluate the percentage of PDPN patients within the
diabetes population based on questionnaire results [14,15,24–
26,40], the description of symptoms in medical records [18,23,41]
or clinical examination [25,26,40]. PDPN severity was deter-
mined by different questionnaires (e.g., BPI and NTSS-6) and
cut-off points, which may affect the comparability of the results.
Furthermore, the review did not identify any studies
comparing the humanistic burden of PDPN patients to the
general population. Therefore, no qualitative data is available to
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people. However, as PDPN patients have significantly worse
HRQoL compared to diabetes patients with no pain and non-
neuropathic pain [40], it can be assumed that PDPN patients
value their HRQoL much lower than the general population.
None of the identified economic burden studies compared the
costs and productivity losses of PDPN patients to diabetes
mellitus patients or the general population. Therefore this
review is unable to provide direct evidence that PDPN patients
incur more healthcare and societal costs compared to these
populations. On the other hand, PDPN patients with mild pain
symptoms have a lower economic burden compared to patients
with moderate to severe pain symptoms. This finding suggests
diabetes mellitus patients without (painful) neuropathy to have
a lower economic burden compared to subjects with PDPN.
In conclusion, European data show that PDPN patients
experience lower HRQoL due to the pain and its impact on
daily functioning in life, the quality and quantity of sleep, and
anxiety/depression levels. In addition, the review found that
increasing severity of painful symptoms is related to larger
impairment of HRQoL. Healthcare costs and impaired pro-
ductivity increase as well with more severe symptoms.
Reducing painful symptoms by treatment in PDPN patients
will lead to improvements in quality of life.
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